 Isoniazid
"Isoniazid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
| Descriptor ID |
D007538
|
| MeSH Number(s) |
D02.442.436 D03.066.349.410 D03.383.725.394.582
|
| Concept/Terms |
Isoniazid- Isoniazid
- Isonicotinic Acid Hydrazide
- Hydrazide, Isonicotinic Acid
Phthivazide- Phthivazide
- Phthivazid
- Isonicotinic Acid Vanillylidenehydrazide
- Acid Vanillylidenehydrazide, Isonicotinic
- Vanillylidenehydrazide, Isonicotinic Acid
- Ftivazide
|
Below are MeSH descriptors whose meaning is more general than "Isoniazid".
Below are MeSH descriptors whose meaning is more specific than "Isoniazid".
This graph shows the total number of publications written about "Isoniazid" by people in this website by year, and whether "Isoniazid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 2 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 2 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 1 | 4 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 2 | 3 | | 2021 | 3 | 2 | 5 | | 2023 | 1 | 5 | 6 | | 2024 | 0 | 1 | 1 | | 2025 | 0 | 2 | 2 | | 2026 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Isoniazid" by people in Profiles.
-
Hendrix J, Al Mubarak R, Reichlen MJ, Tabor ST, Bateman A, Massoudi LM, Rossmassler K, Kaya F, Zimmerman MD, Nielsen H, Wynn EA, Voskuil MI, Robertson GT, Moore CM, Walter ND. Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo. PLoS Pathog. 2026 Apr; 22(4):e1014131.
-
Yengkhom D, Montepiedra G, Masheto G, Wabwire D, Stranix-Chibanda L, Matubu A, Violari A, Theron G, Gupta A, Weinberg A. Tuberculosis preventive therapy in postpartum women with HIV modifies M. tuberculosis-specific and nonspecific immune responses. Front Immunol. 2026; 17:1722621.
-
Béranger A, Solans BP, Miyakawa R, McIlleron H, Tarning J, Shah I, Aruldhas BW, Mathew BS, Kwara A, Peloquin CA, Mukherjee A, Lodha R, Denti P, Capparelli EV, Kiser JJ, Bekker A, Chabala C, Choo L, Turkova A, Gafar F, Ruslami R, Nataprawira HM, Heysell SK, Thomas TA, Velpandian T, Day JN, Bang ND, Dooley K, Savic RM. Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis. Eur Respir J. 2026 Mar; 67(3).
-
Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Wabwire D, Masheto G, Jean-Philippe P, Sterling TR, Weinberg A, Gupta A. Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics. Clin Infect Dis. 2026 Feb 09; 82(1):e156-e164.
-
Kurbatova EV, Dooley KE, Carr W, Stout JE, Nuermberger EL, Phillips PPJ, Scott NA, Upton CM, Ignatius E, Haas M, Walter ND, Traxler RM, Brown NE, Boyd R, Bryant KE, Dixon MG, Savic R, Eichberg C, Hesseling A, Bark C, Benator DA, Muzanyi G, Twycross NS, Fox GJ, Pierre S, Burzynski J, Fitzgerald DW. Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design. Contemp Clin Trials. 2025 Nov; 158:108075.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ektnitphong V, Bauman AA, Massoudi LM, Voskuil MI, Robertson GT, Moore CM, Walter ND. Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0131024.
-
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb; 21(2):e1004356.
-
Brooks KM, Pau AK, Swaim D, Bunn HT, Adeojo L, Peloquin CA, Kumar P, Kovacs JA, George JM. Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):468-473.
-
Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 10; 7(10):708-717.
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Caylà JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|